Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Akero Therapeutics Inc shares valued at $25,210 were sold by Young Jonathan on Sep 11 ’25. At $43.02 per share, Young Jonathan sold 586 shares. The insider’s holdings dropped to 196,898 shares worth approximately $8.31 million following the completion of this transaction.
Also, Yale Catriona sold 659 shares, netting a total of over 28,350 in proceeds. Following the sale of shares at $43.02 each, the insider now holds 90,829 shares.
Before that, White William Richard had sold 659 shares from its account. In a trade valued at $28,350, the Chief Financial Officer traded Akero Therapeutics Inc shares for $43.02 each. Upon closing the transaction, the insider’s holdings decreased to 659 shares, worth approximately $2.44 million.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. As of January 30, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for AKRO. Earlier on January 27, 2025, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for AKRO stock.
Analyzing AKRO Stock Performance
On last trading session, Akero Therapeutics Inc [NASDAQ: AKRO] plunged -0.99% to $42.18. The stock’s lowest price that day was $41.8, but it reached a high of $43.125 in the same session. During the last five days, there has been a drop of approximately -2.47%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 54.28%.
Is Akero Therapeutics Inc subject to short interest?
Stocks of Akero Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.77 million shares to 8.89 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 8.12 million shares. A jump of 8.64% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.07 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.07.
Which companies own the most shares of Akero Therapeutics Inc (AKRO)?
In terms of Akero Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 69.01% from the previous closing price of $42.6. Analysts anticipate Akero Therapeutics Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 4 analysts ranked Akero Therapeutics Inc stock as Buy at the end of 2025. On November 18, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $65.
